Skip to main content
Clinical Trials/ISRCTN90702227
ISRCTN90702227
Active, not recruiting
Phase 1

Phase I trial: Ocular Technology Group International[The full scientific title will be published within 30 months after the end of the trial]

CooperVision International Limited0 sites20 target enrollmentStarted: August 15, 2023Last updated:

Overview

Phase
Phase 1
Status
Active, not recruiting
Enrollment
20

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Exclusion Criteria

  • The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Investigators

Similar Trials

Active, not recruiting
Phase 1
Phase I trial: Ocular Technology Group International CV23-08The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.Not Applicable
ISRCTN66819383CooperVision International Ltd40
Recruiting
Phase 1
ROH-001 ophthalmic solution phase I clinical trial -Single and multiple dose studyHealthy volunteer
JPRN-jRCT2051230128Mantani Tomomi48
Active, not recruiting
Phase 1
A Phase II, pilot clinical trial to evaluate the effects of atorvastatin on Graves' Orbitopathy (GO) in hypercholesterolemic patients with moderate-to-severe and active GO subjected to intravenous glucocorticoid therapy.Graves’ orbitopathy is a disabling and disfiguring disease affecting the eyes observed in approximately 25-30% of patients with Graves’ disease. Its clinical manifestations include exophthalmos, inflammatory signs and symptoms, diplopia, and in most severe cases sight impairment.MedDRA version: 20.0Level: PTClassification code 10004161Term: Basedow's diseaseSystem Organ Class: 10014698 - Endocrine disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]
EUCTR2018-001317-33-ITAZIENDA OSPEDALIERO-UNIVERSITARIA PISANA88
Completed
Not Applicable
Retinal Artery Study in participants with obstructive sleep apnoea treated with continuous positive airway pressureEndothelial functionSleep ApnoeaCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemRespiratory - Sleep apnoea
ACTRN12610000311055Austin Health Department of Cardiology and Institute for Breathing and Sleep30
Completed
Not Applicable
Eye movement desensitization and reprocessing therapy as video-conference psychotherapyA memory of an adverse life event that causes a disturbing memory trace measured by Subjective Unit of Distress (SUD)Mental and Behavioural Disorders
ISRCTN12099530niversity of Worcester24